TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Patients with paradoxical low-flow, low gradient AS linked to higher mortality rate after TAVR
Patients with this specific subtype of severe aortic stenosis, which can sometimes be challenging to diagnose, face a number of additional risks.
Abbott executive who led TAVR, Tendyne divisions announces exit
Chris Waddell, a medtech executive focused on various structural heart technologies, is leaving Abbott after several years to "recharge" and pursue a new opportunity.
Robotic cardiac surgery building momentum thanks to RAVR, other breakthroughs
The sky may be the limit for robotic cardiac surgery in 2026 and beyond.
Medtronic invests $90M in medtech company behind one-of-a-kind TAVR tech
Anteris Technologies is known for its biomimetic transcatheter heart valve, the DurAVR THV System. The device is the first of its kind and has gained considerable attention as the TAVR market continues to grow.
Abbott’s medtech sales climbed in Q4 thanks to strength of heart devices
Abbott pointed to double-digit growth for its Navitor TAVR valve as well as big gains for the TriClip and MitraClip devices. The company also shared positive sales figures for its EP, heart failure and rhythm management portfolios.

old woman or doctor shaking hands with patient

Patients with paradoxical low-flow, low gradient AS linked to higher mortality rate after TAVR

Patients with this specific subtype of severe aortic stenosis, which can sometimes be challenging to diagnose, face a number of additional risks.

Abbott executive who led TAVR, Tendyne divisions announces exit

Chris Waddell, a medtech executive focused on various structural heart technologies, is leaving Abbott after several years to "recharge" and pursue a new opportunity.

Robotic aortic valve replacement (RAVR) is a new minimally invasive treatment option for symptomatic severe aortic stenosis (AS) that uses advanced robotic surgical systems. It has already started gaining momentum as an alternative to both surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR).

Robotic cardiac surgery building momentum thanks to RAVR, other breakthroughs

The sky may be the limit for robotic cardiac surgery in 2026 and beyond.

The DurAVR TAVR system from Anteris Technologies

Medtronic invests $90M in medtech company behind one-of-a-kind TAVR tech

Anteris Technologies is known for its biomimetic transcatheter heart valve, the DurAVR THV System. The device is the first of its kind and has gained considerable attention as the TAVR market continues to grow.

Abbott’s medtech sales climbed in Q4 thanks to strength of heart devices

Abbott pointed to double-digit growth for its Navitor TAVR valve as well as big gains for the TriClip and MitraClip devices. The company also shared positive sales figures for its EP, heart failure and rhythm management portfolios.

Medical societies, medtech companies and clinicians weigh in as CMS considers sweeping TAVR changes

CMS is considering substantial updates to its TAVR policies, including coverage for asymptomatic patients. Some stakeholders are excited, embracing the possibility of expanded indications and fewer restrictions. Others are concerned that the changes would be too much, too soon.

heart data research doctor cardiologist AI

Post-TAVR echocardiography helps predict a patient’s long-term risk of SVD

Postprocedural gradients can tell cardiologists a lot about a patient's long-term risk of structural valve deterioration.

Abbott’s Navitor TAVR valve linked to positive real-world outcomes

The intra-annular, self-expanding Navitor valve gained FDA approval in 2023 for the treatment of high-risk heart patients with severe aortic stenosis. This analysis explores its early impact on patient care.